Mounting evidence suggests that the use of IL-17 inhibitors, including SEC, IXE, and brodalumab in patients with psoriasis does not increase the risk of SARS-CoV-2 infection or worsen the course of COVID-19 [21,22]. This evidence concerns the gene IL17A and psoriasis.